knowledge -WSS

knowledge

author：focus 2025-09-04 03:39:25 - browse：42416

Alex Hogan/STAT

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods.

This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot. After a volatile 2023 that saw biotech stocks hit five-year lows in the fall, the sector had a bull run in the final weeks of the year, spurred by some high-dollar merger agreements and a prevailing sense that the macroeconomic winds were finally shifting in biotech’s direction.

Meanwhile, companies selling digital health services like telemedicine, health plans for virtual care, and AI tools for payers face a crucial year as they scramble to make good on profitability projections. Those companies, along with the country’s most powerful health systems, are seriously exploring AI, even ChatGPT, to help them meet financial milestones.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WSS

White House drug czar issues call for 'recovery

After affirmative action ruling, medical educators look to 'holistic review'

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

A letter from the executive editor: STAT UnitedHealth investigation

How to save PrEP access — and even expand it

hotspot

knowledge

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Alkermes shareholders re

Healthy food access boosts outcomes in two studies

Alkermes shareholders re

FDA reorg will put new emphasis on investigations, sources say

Medicare proposal to cover medical devices draws a mixed reaction

Wildfire smoke exposes gaps in outdoor worker protections

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Drug repurposing or repositioning? The language matters

focus

Medical records are filled with copy

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Cancer drug shortages should be causing more outrage

Medical leaders decry Supreme Court decision on affirmative action

Heart attack and stroke risk calculators need revising

NIH chief: government has fallen behind pharma on clinical trials

entertainment

focus

knowledge

Wikipedia